Immunology

#Business #Drug development #Drug discovery #Enabling technologies #Immunology #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA #Stem cells

GSK and CureVac in mRNA technology collaboration

27 July 2020 Image: CDC GlaxoSmithKline and CureVac are collaborating for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform. mRNA (messenger RNA) technology is… Read More

#News

#Cell therapy #Drug discovery #Gene therapy #Genetics / genomes #Immunology #Lead discovery #Oncology #Regenerative Medicine #RNA #Stem cells #Therapeutics

Fine-tuning adoptive cell therapy could create more efficient immunotherapies

23 July 2020 Image: National Cancer Institute Adoptive cell transfer immunotherapy is one of the most promising new treatments for people with hard-to-treat cancers. However, the process is complex and needs fine-tuning in order to develop more treatment strategies that will work for more people. In a new… Read More

#News

#Biologics / Biotechnology #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Immunology #Immunology / Virology & Vaccines #Precision medicine #RNA #Therapeutics

Over £100m UK cash boost to produce millions of doses of COVID-19 vaccine

The UK’s capability to manufacture vaccines has received a substantial boost, as the UK government has announced an additional £100 million to ensure that any successful COVID-19 vaccine can be produced at scale in the UK. The investment will fund a Cell and Gene Therapy Catapult Manufacturing Innovation… Read More

#Covid-19 #News

#Assay development optimisation & technology #Business #Drug development #Drug discovery #Drug targets #High throughput screening #Immunology #Lead discovery #Screening #Stem cells #Therapeutics

AbCellera agreement to use humanised mice platform for antibody discovery

21 July 2020 Image: Henry Lai AbCellera has entered into an agreement with Alloy Therapeutics to use the ATX-Gx humanised mice platform to enable best-in-class in vivo human antibody discovery for its partner programs. Under the terms of the agreement, AbCellera will offer its biotech and pharma partners… Read More

#News

#Academic #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK pharma body says COVID-19 vaccine may still be many months away

Image: Dimitri Houtteman A COVID-19 vaccine being developed by Oxford University and AstraZeneca has generated an immune response in a study of roughly 1,000 patients, according to interim results. The Association of the British Pharmaceutical Industry (ABPI) has responded to the results of the Oxford – AstraZeneca vaccine… Read More

#Covid-19 #News

#Academic #Biologics / Biotechnology #Business #Clinical trials #Drug development #Drug discovery #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #RNA #Stem cells

Study shows Oxford coronavirus vaccine produces strong immune response

A team of scientists at Oxford University’s Jenner Institute and Oxford Vaccine Group has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus. The results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety… Read More

#Covid-19 #News

#Biologics / Biotechnology #Business #Clinical trials #Drug discovery #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA

UK secures portfolio of promising vaccines candidates from BioNTech/Pfizer alliance

Millions of people could be vaccinated against coronavirus as the UK secures early access to 90 million doses of promising Covid-19 vaccine candidates. The UK government has agreed significant partnerships with leading pharmaceutical and vaccine companies BioNTech/Pfizer and Valneva that are developing new vaccines to protect people against… Read More

#Covid-19 #News

#Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Lead discovery #Regulatory

Phase 1 clinical trial of COVID-19 vaccine begins at University of Queensland

The next critical phase for The University of Queensland’s (UQ) COVID-19 vaccine is underway, with the research effort moving out of the lab and into human trials. Healthy adult volunteers have received the first dose of the vaccine at the Brisbane clinic of phase 1 clinical trials specialist,… Read More

#Covid-19 #News

#Business #Cellular & Molecular biology #Clinical trials #Drug discovery #Imaging #Immunology #Lead discovery #Screening #Stem cells #System biology

Llama antibodies may neutralise COVID-19, study finds

Antibodies derived from llamas have been shown to neutralise the SARS-CoV-2 virus in lab tests, UK researchers have found. The team involves researchers from the Rosalind Franklin Institute, Oxford University, Diamond Light Source and Public Health England. They hope the antibodies – known as nanobodies due to their… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Precision medicine #Preclinical #RNA #Therapeutics #Translational #Translational chemistry

Cancer vaccine shows promising signs

The Translational Research Institute-based Mater researchers in partnership with The University of Queensland have developed a new cancer vaccine, which has shown promising signs in preclinical laboratory studies. Funded by grants from the Worldwide Cancer Research in the United Kingdom, and Mater Foundation, the new vaccine could be potentially… Read More

#Covid-19 #News

#Cell therapy #Clinical specialities #Clinical trials #Drug development #Immunology #Microbiology #Preclinical #RNA #Stem cells #System biology

Researchers find promising therapy to fight epidemic of liver disease

9 July 2020 Image: Science in HD So far there are no approved drugs for Non-Alcoholic Fatty Liver Disease In an effort to combat a growing worldwide epidemic of Nonalcoholic Fatty Liver Disease (NAFLD), scientists have discovered a new target and a new therapy that has shown promising… Read More

#News

#Academic #Assay development optimisation & technology #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Microfluidics #Molecular medicine #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Cell ‘membrane on a chip’ could speed up screening of drug candidates for COVID-19

Researchers have developed a human cell ‘membrane on a chip’ that allows continuous monitoring of how drugs and infectious agents interact with our cells. It may soon be used to test potential drug candidates for COVID-19. The researchers, from the University of Cambridge, Cornell University and Stanford University,… Read More

#Covid-19 #News

#Academic #Analysis #Assay development optimisation & technology #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

MMR vaccination might protect children from COVID-19

Image: CDC A group of Lithuanian and Kurdish scientists have raised a hypothesis that the measles, mumps, and rubella (MMR) vaccine could protect children from COVID-19. The hypothesis is based on the discovered sequence similarity of the 30 amino acid residues between glycoproteins of SARS-CoV-2, measles and rubella… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microfluidics #Molecular medicine #Nanomedicine / nanotechnology #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Therapeutics #Translational #Translational chemistry

Engineers use ‘DNA origami’ to identify vaccine design rules

30 June 2020 Image: Glen Carrie In lab tests, virus-like DNA structures coated with viral proteins provoke a strong immune response in human B cells, by Ann Trafton, MIT News Office By folding DNA into a virus-like structure, MIT researchers have designed HIV-like particles that provoke a strong immune… Read More

#News

#Animal models #Computational chemistry #Gene editing #Immunology #Protein chemistry / Proteomics #RNA #Therapeutics

Experimental peptide targets Covid-19

Computational modeling yields a protein fragment that could bind to coronavirus spike proteins and destroy them by Anne Trafton, MIT News Office The research described in this article has been published on a preprint server but has not yet been peer-reviewed by scientific or medical experts. Using computational models… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Microbiology #RNA #Stem cells #System biology

Taconic Biosciences to distribute critical COVID-19 mouse model

Taconic Biosciences has announced an exclusive agreement with the University of Texas Medical Branch at Galveston (UTMB) to distribute humanised ACE2 mice for coronavirus research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter cells, causing infection. Due to differences between the mouse and human… Read More

#Covid-19 #News